GSK company Presentation information about compay

Editor's Notes

• #10: This slide outlines GSK’s international management environment, highlighting its approach to navigating global markets. Key areas include GSK’s global market footprint, focusing on strategic regions and key markets for growth. The company also emphasizes regulatory and cultural adaptability to ensure compliance with local laws and alignment with cultural expectations. Finally, GSK employs strategic market operations to optimize its international business practices, addressing both the challenges and opportunities of operating in diverse markets globally. These factors collectively support GSK’s competitive positioning on a global scale, as reported in 2023.
• #11: Business model of GSK world wide
• #13: PwC’s collaboration with GSK is multifaceted, addressing critical industry challenges through joint initiatives. A notable project, the Medicines Manufacturing Innovation Centre, focuses on improving the pharmaceutical supply chain, particularly for challenging drug types. Together, GSK and PwC are also researching treatments for ‘undruggable’ diseases, targeting conditions traditionally difficult to treat. Additionally, the collaboration emphasizes sustainability, aiming to incorporate eco-friendly practices in healthcare manufacturing, which aligns with both companies' commitment to responsible business practices and future-focused solutions.
• #14: This slide presents GSK's approach to the Triple Bottom Line (TBL) model, which emphasizes the balance of People, Planet, and Profit. In the "People" pillar, GSK invests in community health initiatives, improving healthcare access and supporting public health. For "Planet," the company focuses on reducing its environmental footprint through carbon reduction and sustainable resource use. Under "Profit," GSK aims for strong financial performance while ensuring its growth aligns with responsible social and environmental practices. Together, these elements support GSK's commitment to sustainable and equitable growth,
• #15: This slide focuses on GSK’s governance score, which reflects the company’s alignment with industry standards in areas such as board independence, transparency in operations, and stakeholder engagement. These metrics emphasize GSK’s commitment to strong governance practices, ensuring accountability and ethical management. The diagram highlights specific governance initiatives, including automation for efficiency, data harmonization, and an internal control framework. Together, these initiatives support clearer roles, consistent standards, and strengthened controls, all of which contribute to GSK’s high governance performance as reported in 2023.
• #16: This slide provides key actionable recommendations for GSK to enhance its governance and sustainability efforts. These include enhancing board diversity to bring varied perspectives to leadership, increasing community engagement to strengthen stakeholder relationships, and adopting green technologies to reduce environmental impact. Additionally, strengthening ethical practices across operations and implementing continuous governance training for employees can further reinforce GSK’s commitment to responsible and transparent business practices. Together, these recommendations aim to support GSK's long-term growth and reputation in line with best governance standards.
• #17: GSK’s future outlook is defined by an ambitious commitment to reach over 2.5 billion people by 2030, driven by innovation and strategic pipeline growth. The company’s long-term focus on advancing vaccines and specialty medicines, particularly in infectious disease and oncology, is foundational to its growth strategy. Furthermore, GSK’s dedication to sustainability, with clear goals in eco-friendly R&D and sourcing practices, aligns with its objective of responsible, impactful healthcare. This forward-looking approach places GSK in a strong position to address global health challenges effectively and sustainably.